Cecilia Brown

Lung Cancers Today

Patients with lung cancer who receive the COVID-19 vaccine have a &ldquo;markedly lower&rdquo; antibody titer than those who are healthy, according to a new study highlighting the need for &ldquo;comprehensive protective measures&rdquo; against COVID-19 in patients with lung cancer.A team of researchers evaluated the immunogenicity and safety of the COVID-19 vaccine in high-risk populations by evaluating results from eight studies including 1,220 patients with lung cancer and 599 people who were healthy.The study showed that IgG titers against the SARS-CoV-2 spike protein &ldquo;were markedly reduced&rdquo; in patients with lung cancer compared to people who served as healthy controls, with a statistically significant difference (P=.002) between the groups.However, the safety profile of the vaccine was &ldquo;comparable between the two groups,&rdquo; in terms of local reactions after the first vaccine (risk ratio [RR]=0.90, 95% CI, 0.68-1.19), systemic reactions after the first vaccine (RR=0.92; 95% CI: 0.51-1.66), local reactions after the second vaccine (RR=0.81, 95% CI: 0.54-1.19), and systemic reactions after the second vaccine (RR=1.20, 95% CI, 0.65-2.21.)The researchers concluded that with the antibody titer in patients with lung cancer being &ldquo;markedly lower,&rdquo; it&rsquo;s important to recognize that &ldquo;fatalities from COVID-19 may transpire in these people notwithstanding vaccination and that &ldquo;comprehensive protective measures must continue to be implemented to safeguard lung cancer patients who have received two doses of the COVID-19 vaccination against COVID-19.&rdquo;Source: <a href="https://karger.com/iaa/article-abstract/doi/10.1159/000542281/916244/Immunogenicity-and-safety-of-COVID-19-vaccines-in">International Archives of Allergy and Immunology</a>

Eric Singhi, MD

ASCO 2025: Dr. Singhi Shares Key Lung Cancer Studies to Watch

Conference Coverage

Stephen V. Liu, MD

ASCO 2025: Dr. Liu Discusses the Most Anticipated Thoracic Oncology Data To Be Presented

Phase 3 IMforte Trial Meets Primary Endpoints of OS and PFS in Extensive-Stage SCLC

Small Cell Lung Cancer

The Accelerated Approval of Telisotuzumab Vedotin for NSCLC: Dr. Singhi Shares What Clinicians Should Know

Non-Small Cell Lung Cancer

Mara B. Antonoff, MD

Operating in Oligometastatic Disease: Dr. Antonoff Shares Patient Selection Considerations

Lung Cancer

Lung Cancer Screening: Study Explores Impact of Eligibility Differences by Smoking History

Latest News

Is the COVID-19 Vaccine Effective for Patients With Lung Cancer?

Patients with lung cancer who receive the COVID-19 vaccine have a “markedly lower” antibody titer than those who are healthy.